Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
- PMID: 39759148
- PMCID: PMC11695192
- DOI: 10.3389/fonc.2024.1507608
Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
Abstract
Background: Although the number of studies on sorafenib for hepatocellular carcinoma (HCC) is increasing during the past two decades, no detailed scientometric examination of its knowledge framework has been undertaken. Therefore, we performed a bibliometric analysis on this topic.
Methods: VOSviewer and CiteSpace were utilized to analyze the articles regarding sorafenib for HCC from 2005 to 2024, which were retrieved from the Web of Science Core Collection (WoSCC) database.
Results: There were 7,667 articles related to sorafenib in HCC were retrieved from the WoSCC database, and they covered 99 countries/regions, 5,640 institutions, and 30,450 authors. The most published literature of countries and institutions were China and Sun Yat-sen University, respectively. Cancers is the journal with the most papers published in this field, and the journal with the most co-citations is N Engl J Med. Among authors, Masatoshi Kudo has published the most research papers, and the most co-citations go to JM Llovet. The keywords "survival", "apoptosis", "efficacy", "transarterial chemoembolization", "lenvatinib", etc. represent the current hotspots in this field.
Conclusions: We identified current hotspots and trends by bibliometric analysis in sorafenib-HCC field, which might provide valuable guidance for future researches. Further explorations are supposed to conduct the continued study of HCC apoptosis, large-scaled clinical trials with international cooperations, and comprehensive treatments including multiple systemic or locoregional approaches in patients with HCC.
Keywords: apoptosis; bibliometric analysis; hepatocellular carcinoma; liver cancer; sorafenib.
Copyright © 2024 Meng, Luo, Zhao, Zhang, Liu, Li, Du and Li.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures






Similar articles
-
Bibliometric study of immunotherapy for hepatocellular carcinoma.Front Immunol. 2023 Aug 4;14:1210802. doi: 10.3389/fimmu.2023.1210802. eCollection 2023. Front Immunol. 2023. PMID: 37600802 Free PMC article. Review.
-
Mapping research trends of transarterial chemoembolization for hepatocellular carcinoma from 2012 to 2021: A bibliometric analysis.World J Methodol. 2023 Sep 20;13(4):345-358. doi: 10.5662/wjm.v13.i4.345. eCollection 2023 Sep 20. World J Methodol. 2023. PMID: 37771871 Free PMC article.
-
Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study.Front Immunol. 2022 Jan 31;13:815575. doi: 10.3389/fimmu.2022.815575. eCollection 2022. Front Immunol. 2022. PMID: 35173728 Free PMC article.
-
A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014-2022).Front Pharmacol. 2023 Jun 14;14:1159286. doi: 10.3389/fphar.2023.1159286. eCollection 2023. Front Pharmacol. 2023. PMID: 37388443 Free PMC article.
-
A bibliometric and visual analysis based on immune checkpoint inhibitors for hepatocellular carcinoma: 2014 - 2024.Front Pharmacol. 2025 Apr 7;16:1520055. doi: 10.3389/fphar.2025.1520055. eCollection 2025. Front Pharmacol. 2025. PMID: 40260385 Free PMC article.
Cited by
-
Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation.Front Pharmacol. 2025 Jul 23;16:1581820. doi: 10.3389/fphar.2025.1581820. eCollection 2025. Front Pharmacol. 2025. PMID: 40771926 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous